Pradofloxacin (trade name Veraflox) is a 3rd generation enhanced spectrum veterinary antibiotic of the fluoroquinolone class. It was developed by Bayer HealthCare AG, , and received approval from the European Commission in April 2011 for prescription-only use in veterinary medicine for the treatment of in dogs and cats.

Property Value
dbo:abstract
  • Pradofloxacin (trade name Veraflox) is a 3rd generation enhanced spectrum veterinary antibiotic of the fluoroquinolone class. It was developed by Bayer HealthCare AG, , and received approval from the European Commission in April 2011 for prescription-only use in veterinary medicine for the treatment of in dogs and cats. (en)
dbo:thumbnail
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2019-08-25 10:18:53Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 18096649 (xsd:integer)
dbo:wikiPageLength
  • 6237 (xsd:integer)
dbo:wikiPageModified
  • 2019-08-25 10:18:50Z (xsd:date)
dbo:wikiPageOutDegree
  • 26 (xsd:integer)
dbo:wikiPageRevisionID
  • 912404404 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Pradofloxacin (trade name Veraflox) is a 3rd generation enhanced spectrum veterinary antibiotic of the fluoroquinolone class. It was developed by Bayer HealthCare AG, , and received approval from the European Commission in April 2011 for prescription-only use in veterinary medicine for the treatment of in dogs and cats. (en)
rdfs:label
  • Pradofloxacin (en)
owl:sameAs
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is foaf:primaryTopic of